Calgary, Alberta - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the 'Company' or 'Marvel'), is pleased to announce that the Company has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or hallucinations that occur with psychedelics which include ketamine, LSD and tryptamine derivatives such as DMT and psilocybin.

Marvel has identified a series of compounds inspired by known psychedelic molecules, that appear to be active as anti-depressants in pre-clinical testing. The compounds were administered for seven days, and preliminary evidence found multiple molecules with the same core structure capable of reducing depressive symptoms as measured in the widely accepted forced swim test. Early indications are extremely positive, with the swim test producing 2 positive indicators that exhibited strong potential for treatment.

Key features of the first class of molecules that Marvel has developed are: fast acting, orally available, water soluble, no evidence of hallucinatory activity, significantly better (p

(C) 2021 Electronic News Publishing, source ENP Newswire